Press release
SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health
About this update from Siga Technologies Inc.
[{"type":"text","content":"NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in a panel discussion at the Non-Conventional Threats (NCT) Asia Virtual Conference.\n The panel discussion titled, “COVID-19: Insights on an Epidemic Outbreak” will take place at 12:00 p.m. Malaysia Time on Friday, November 13, 2020 with Dr. Hruby speaking as one member of the panel at the conference. “With the COVID-19 pandemic continuing its devastating global impact, preparedness for the possibility of future pandemics are of increasing importance for governments worldwide. We look forward to providing information about TPOXX in addressing a potential smallpox outbreak, which is far more lethal than COVID-19,” said Dr. Hruby. ABOUT SIGA TECHNOLOGIES, INC. and TPOXX® SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX® is a novel small-molecule drug and the US maintains a stockpile of 1.7 million courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX® was approved by the FDA for the treatment of smallpox in 2018. The full label is here: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253. In September 2018, SIGA signed a contract potentially worth more than $600 million with BARDA for additional procurement and development related to both oral and intravenous formulations of TPOXX®. For more information about SIGA, please visit www.siga.com. About Smallpox1 Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research ...